Indica Labs

Indica Labs is an AI-powered digital pathology company offering a comprehensive suite of software platforms and services that span the full continuum from research and discovery through clinical diagnostics. The company's flagship HALO software suite integrates artificial intelligence throughout, enabling pathologists, scientists, and clinical teams to perform advanced image analysis, biomarker quantification, collaborative image management, and clinical trial support. Indica Labs serves a global customer base that includes leading pharmaceutical companies, academic medical centers, cancer research institutes, and diagnostic laboratories.

With deployments across all top 20 pharmaceutical companies, thousands of global installations, hundreds of employees operating in 12 countries, and thousands of peer-reviewed customer publications, Indica Labs has established itself as a market leader in computational and digital pathology. Its platforms are used for both preclinical and clinical applications, supporting workflows ranging from basic science research to FDA-cleared primary diagnosis.

HALO Platform — Research and Discovery

• AI-powered image analysis tools designed to advance pathology research and preclinical studies
• Collaborative image management capabilities enabling teams to share and review whole slide images across institutions
• Supports quantification of immunohistochemical stains, multiplex imaging modalities including MIBI and CODEX/Akoya, RNA-ISH/RNAscope, and tissue microarray data
• Cell segmentation, serial image alignment, and export of quantitative data and FCS files
• HALO AI module allows users to rapidly train AI models for tissue classification tasks such as tumor versus normal tissue and tumor epithelium versus stroma

HALO Platform — Clinical and Diagnostic

• HALO AP Dx: An FDA-cleared, case-centric pathology platform supporting primary diagnosis, remote working, and routine anatomic pathology workflows
• Comprehensive suite of tools for image evaluation, collaboration, and clinical trial management
• Deployed in secure cloud environments, including AWS-hosted infrastructure, to support enterprise-wide clinical and research use cases
• Enables migration of legacy digital pathology databases into centralized HALO environments with minimal downtime and zero data loss

HALO Clinical AI Solutions

• Prostate AI: CE-IVD marked AI tool that detects and grades prostate adenocarcinoma in core needle biopsy specimens
• Lung PD-L1 AI: Quantifies PD-L1 expression in non-small cell lung cancer (NSCLC) immunohistochemistry
• Breast IHC AI: Quantifies HER2, ER, PR, and Ki67 IHC expression levels in primary invasive breast cancer
• Artifact Detection AI: Detects air bubbles, tissue folds, and other common artifacts present in H&E- and IHC-stained whole slide images
• Lung Tumor Content AI: Quantifies tumor content and generates tumor density heatmaps to guide region-of-interest selection for macrodissection in NSCLC
• Colorectal Tumor Content AI: Quantifies tumor content and generates tumor density heatmaps to guide macrodissection in colorectal cancer

Services

• Pharma Services: AI-enabled services tailored to pharmaceutical research and drug development workflows
• HALO Cloud Services: AWS-hosted deployment option that reduces infrastructure costs and facilitates cross-institutional collaboration
• Database migration services to help organizations transition from legacy platforms such as Aperio eSlideManager into centralized HALO environments

Integrations, Compliance, and Notable Partnerships

• FDA-cleared platform (HALO AP Dx) for primary diagnostic use in anatomic pathology
• CE-IVD marked clinical AI solutions for prostate, lung, and breast pathology applications
• Strategic partnership with Leica Biosystems to develop and deliver next-generation AI-enabled computational pathology solutions
• Partnership with Lunit to enable interoperable workflow integration of AI solutions for pathology labs
• Enterprise deployments at institutions including the National Cancer Institute, University of Washington, University of California San Francisco, University of Bern, IPATIMUP, AstraZeneca, and Versant
• Cloud deployments on AWS designed to meet institutional security and compliance requirements

Indica Labs offers an end-to-end digital pathology workflow that connects basic science research to clinical diagnostics through its integrated HALO product ecosystem. The company's combination of regulatory-cleared software, validated clinical AI tools, cloud infrastructure, and expert services makes it a comprehensive partner for life sciences organizations seeking to advance both research productivity and patient care through AI-powered pathology.